POMC and medullary thyroid gland carcinoma: In a small prospective study, the analysis of basal and stimulated adrenal function in 12 patients receiving lenvatinib and vandetanib for advanced radioiodine refractory differentiated or medullary thyroid cancer, respectively, revealed a gradual ACTH increase with normal cortisol levels in 10 patients complaining of fatigue.